Incorporation of Thalidomide into Up-Front Double Autologous Stem-Cell Transplantation (ASCT) for Multiple Myeloma Improves the Outcome in Comparison with Double ASCT without Thalidomide. Analysis of Baseline Factors Predicitve of Outcome.Elena Zamagni, Michèle Cavo, Chiara Nicci et al.|Blood|2007Cited by 3
Baseline Thrombophilic Alterations and Risk of Venous Thromboembolism in 266 Multiple Myeloma Patients Primarily Treated with Thalidomide and High-Dose Dexamethasone.Elena Zamagni, Michèle Cavo, Lelia Valdrè et al.|Blood|2007Cited by 1